ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

Autor: Enriqueta Felip, Josep Tabernero, Maria De Santis, Emile Voest, Mark Robson, Fatima Cardoso, Elisabeth G E de Vries, Fedro Alessandro Peccatori, Svetlana Jezdic, Giannis Mountzios, Smita Bhatia, Alexandru Eniu, Luzia Travado, Ulrich Keilholz, Jonas Bergh, Jan Buckner, Friedrich Stiefel, Ahmad Awada, Cristiana Sessa, Olivier Michielin, Marc Ernstoff, Ben Markman, Lisa Licitra, Rossana Berardi, Jill Gilbert, Lidia Schapira, Eva Schernhammer, Jeffrey S Weber, Heinz-Josef Lenz, Piotr Rutkowski, Jennifer Duff, Axel Grothey, Yuichiro Ohe, Saskia Litiere, Hans Wildiers, Christian Dittrich, Michael Kosty, Doug Pyle, Nagi El-Saghir, Jean-Pierre Lotz, Pia Österlund, Nicholas Pavlidis, Gunta Purkalne, Susana Banerjee, Jan Bogaerts, Paolo Casali, Edward Chu, Julia Lee Close, Bertrand Coiffier, Roisin Connolly, Sarah Coupland, Luigi De Petris, Don S Dizon, Linda R Duska, Martin F Fey, Nicolas Girard, Andor W J M Glaudemans, Priya K Gopalan, Stephen M Hahn, Diana Hanna, Christian Herold, Jørn Herrstedt, Krisztian Homicsko, Dennie V Jones, Lorenz Jost, Saad Khan, Alexander Kiss, Claus-Henning Köhne, Rainer Kunstfeld, Stuart Lichtman, Thomas Lion, Lifang Liu, Patrick J Loehrer, Merry Jennifer Markham, Marius Mayerhoefer, Johannes G Meran, Elizabeth Charlotte Moser, Timothy Moynihan, Torsten Nielsen, Kjell Öberg, Antonio Palumbo, Michael Pfeilstöcker, Chandrajit Raut, Scot C Remick, Roberto Salgado, Martin Schlumberger, Hans-Joachim Schmoll, Lowell Schnipper, Charles L Shapiro, Julie Steele, Cora N Sternberg, Florian Strasser, Roger Stupp, Richard Sullivan, Marcel Verheij, Everett Vokes, Jamie Von Roenn, Yosef Yarden

Publikováno v: ESMO Open, Vol 1, Iss 5 (2016)

The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) are publishing a new edition of the ESMO/ASCO Global Curriculum (GC) thanks to contribution of 64 ESMO-appointed and 32 ASCO-appointed authors. Firs

Externí odkaz: https://doaj.org/article/03442ec458e245ef83ebe8453a3f265c

BRCA mutation screening and patterns among high-risk Lebanese subjects

Autor: Chantal Farra, Christelle Dagher, Rebecca Badra, Miza Salim Hammoud, Raafat Alameddine, Johnny Awwad, Muhieddine Seoud, Jaber Abbas, Fouad Boulos, Nagi El Saghir, Deborah Mukherji

Publikováno v: Hereditary Cancer in Clinical Practice, Vol 17, Iss 1, Pp 1-7 (2019)

Abstract Background Previous studies have suggested that the prevalence of BRCA1 and 2 mutations in the Lebanese population is low despite the observation that the median age of breast cancer diagnosis is significantly lower than European and North A

Externí odkaz: https://doaj.org/article/766437263e894151ba20442bc3daa864

Data from Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

Autor: Debu Tripathy, Yan Ji, Arunava Chakravartty, Yongyu Wang, Craig Wang, Nadia Solovieff, Claudia Gasch, Ruth O'Regan, Nagi El-Saghir, Sherko Kuemmel, Young-Hyuck Im, Michelino De Laurentiis, Paul Wheatley-Price, K. Govind Babu, Kyung Hae Jung, Rafael Villanueva Vazquez, Saul Campos-Gomez, Keun Seok Lee, Joohyuk Sohn, Louis Chow, Sara Hurvitz, Nadia Harbeck, Fatima Cardoso, Aditya Bardia, Fabio Franke, Marco Colleoni, Seock-Ah Im, Yen-Shen Lu

Purpose:Ribociclib plus endocrine therapy (ET) demonstrated a statistically significant progression-free survival and overall survival (OS) benefit in the phase III MONALEESA-7 trial of pre-/perimenopausal patients with hormone receptor (HR)-positive

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::304edc6d2f98864829bedb6942c99952
https://doi.org/10.1158/1078-0432.c.6532502.v1

Supplementary Table from Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

Autor: Debu Tripathy, Yan Ji, Arunava Chakravartty, Yongyu Wang, Craig Wang, Nadia Solovieff, Claudia Gasch, Ruth O'Regan, Nagi El-Saghir, Sherko Kuemmel, Young-Hyuck Im, Michelino De Laurentiis, Paul Wheatley-Price, K. Govind Babu, Kyung Hae Jung, Rafael Villanueva Vazquez, Saul Campos-Gomez, Keun Seok Lee, Joohyuk Sohn, Louis Chow, Sara Hurvitz, Nadia Harbeck, Fatima Cardoso, Aditya Bardia, Fabio Franke, Marco Colleoni, Seock-Ah Im, Yen-Shen Lu

Supplementary Table from Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13fa487cd5dbbb5bcb14d192dffde384
https://doi.org/10.1158/1078-0432.22487348.v1

The impact of young age (< 40 years) on the outcome of a cohort of patients with primary non-metastatic breast cancer: analysis of 10-year survival of a prospective study

Autor: Youssef Bouferraa, Yolla Haibe, Andrea Chedid, Elio Jabra, Maya Charafeddine, Sally Temraz, Deborah Mukherji, Nagi El Saghir, Ali Shamseddine

Publikováno v: BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
BMC Cancer

Background The role of young age ( Methods A total of 119 female patients with newly diagnosed non-metastatic breast cancer were recruited at the American University of Beirut Medical Center (AUBMC) between July 2011 and May 2014. Patients were recru

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04d14e0a8b401c3b48912a0e5614b922
https://doaj.org/article/6ace2272bcfa4793a05ffc9c1ca33397